Funding Opportunity PAR-17-327 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs or drug candidates for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel Agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. PoC studies must evaluate the drugs impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private funding for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development.

Notice NOT-NS-17-035 from the NIH Guide for Grants and Contracts

Notice NOT-AG-17-011 from the NIH Guide for Grants and Contracts

Notice NOT-TR-17-019 from the NIH Guide for Grants and Contracts

Notice NOT-OD-17-089 from the NIH Guide for Grants and Contracts

Notice NOT-DA-17-042 from the NIH Guide for Grants and Contracts

Notice NOT-CA-17-069 from the NIH Guide for Grants and Contracts

Notice NOT-GM-17-014 from the NIH Guide for Grants and Contracts

Notice NOT-CA-17-070 from the NIH Guide for Grants and Contracts

Notice NOT-CA-17-071 from the NIH Guide for Grants and Contracts

Notice NOT-DA-17-049 from the NIH Guide for Grants and Contracts

Notice NOT-GM-17-012 from the NIH Guide for Grants and Contracts

Notice NOT-TR-17-021 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-18-017 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic or clinical research applications that investigate central neural mechanisms of age-related hearing loss in older adults and/or in relevant animal models. This FOA is driven by the need to address a major gap in our understanding of the central pathways and neural networks that are involved in hearing loss and how these may be altered in the context of the aging brain, as well as how natural aging influences central auditory plasticity.

Notice NOT-GM-17-013 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HD-18-009 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications from U.S. institutions to support Research Units (RUs) within the Global Network for Womens and Childrens Health Research at NICHD. RUs will consist of U.S.-based research centers applying in partnership with research centers in low income countries as defined by the World Bank. The RUs within the Global Network will participate in addressing the major causes of maternal, neonatal, infant, and early childhood morbidity and mortality through the conduct of clinical research. The grantees will become part of a cooperative network in scientific partnership with the NIH to conduct multi-enter observational studies and randomized clinical trials evaluating disease process, health and wellness outcomes, and results from interventions in resource-poor settings.

Negotiable: Paramount Recruitment: Software Developer (Python) - Permanent - Cambridgeshire Competitive salary, Bioinformatics and Genomics! A new Software Developer (strong in Python) is required to join one of the UK's leading companies in genomics-based research. Cambridgeshire, England

£31,115 to £39,004 plus excellent benefits: Wellcome Trust Sanger Institute: A postdoctoral position is available at the Wellcome Trust Sanger Institute under the leadership of... Cambridge

Notice NOT-TR-17-020 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-EY-17-002 from the NIH Guide for Grants and Contracts. A central goal of the BRAIN Initiative is to understand how electrical and chemical signals code information in neural circuits and give rise to sensations, thoughts, emotions and actions. While currently available technologies can provide some understanding, they may not be sufficient to accomplish this goal. For example, non-invasive technologies are low resolution and/or provide indirect measures such as blood flow, which are imprecise; invasive technologies can provide information at the level of single neurons producing the fundamental biophysical signals, but they can only be applied to tens or hundreds of neurons, out of a total number in the human brain estimated at 85 billion.